Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cook gets US nod for pivotal PATENCY trial:

This article was originally published in Clinica

Executive Summary

The US FDA has conditionally approved Cook's pivotal trial of its paclitaxel- eluting coronary stent for combating restenosis. PATENCY study, which will begin enrolling 200 patients at 20 sites immediately, is expected to keep Cook on track to launch its Logic PTX drug-eluting stent in the US next year, says the Bloomington, Indiana firm. In a separate announcement, Cook said it had gained US go-ahead to enrol 100 patients at 10 institutions in a randomised pilot study to assess its device as a treatment for in-stent restenosis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel